According to key opinion leaders, positive SURMOUNT-5 results, alongside Lilly’s business strategy, means Zepbound will overtake competitors.

Cocrystal Pharma has announced its intent to extend enrolment for its Phase IIa human challenge trial of CC-42344 ...

According to GlobalData, non-industry sponsored trials lead rare disease indications, accounting for 55.6% of all trials since 2004.

The global trial is intended to offer treatment options for paediatric patients with B-cell non-Hodgkin lymphoma. Credit: © University of Birmingham 2025. The ...

The Phase IIb trial included 450 bunionectomy patients, who received treatment orally twice a day for 72 hours. Credit: Kim Kuperkova / Shutterstock. Taiwanese pharmaceutical company Xgene ...

The trial involves 60 individuals of five to 18 years of age with autism spectrum disorder. Credit: illustrissima / Shutterstock. Israeli Medical Cannabis Agency (IMCA) at the Ministry of Health has ...